Search results
Results from the Tech24 Deals Content Network
ACTG logo. The AIDS Clinical Trials Group network (ACTG) is one of the largest HIV clinical trials organizations in the world, playing a major role in setting standards of care for HIV infection and opportunistic diseases related to HIV and AIDS in the United States and the developing world. The ACTG is composed of, and directed by, leading ...
iPrEx logo. iPrEx (from Spanish: Iniciativa Profilaxis Pre-Exposición, "pre-exposure prophylaxis initiative") was a phase III clinical trial to determine whether the antiretroviral medication emtricitabine/tenofovir (as tenofovir disoproxil fumarate) could safely and effectively prevent HIV acquisition through sex in men who have sex with men and transgender women.
The HPTN is a global network of investigators from Clinical Trials Units (CTUs), Leadership and Operations Center (LOC) which includes recognized experts in HIV prevention, leadership partners from the network Laboratory Center (LC) and Statistical and Data Management Center (SDMC) and various working groups (WGs) and committees charged with the scientific management and operational support of ...
The study, called the PURPOSE 1 trial, involved adolescent girls and young women in South Africa and Uganda who were randomly assigned to either receive lenacapavir injections every 26 weeks or ...
The HIV Vaccine Trials Network (HVTN) is a non-profit organization which connects physicians and scientists with activists and community educators for the purpose of conducting clinical trials seeking a safe and effective HIV vaccine. Collaboratively, researchers and laypeople review potential vaccines for safety, immune response, and efficacy.
Pre-exposure prophylaxis is a general term for the use of medications to prevent the spread of disease in people who have not yet been exposed to a disease-causing agent. The term PrEP now typically refers to the use of antiviral drugs as a strategy for the prevention of HIV/AIDS. [ 1] PrEP is one of a number of HIV prevention strategies for ...
SAV001. SAV001-H is the first candidate preventive HIV vaccine using a killed or "dead" version of the HIV-1 virus ( inactivated vaccine ). The vaccine was developed by Dr. Chil-Yong Kang and his research team at Western University’s Schulich School of Medicine & Dentistry in Canada. The results of the Phase I clinical trial, completed in ...
Moderna has begun early-stage clinical trials of an HIV mRNA vaccine, the company announced this week.On Thursday, it administered the first doses of a shot it co-developed with the International ...